Vallon Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference
03 mars 2021 08h35 HE
|
Vallon Pharmaceuticals Inc.
PHILADELPHIA, PA, March 03, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the...
Vallon Pharmaceuticals Appoints Marella Thorell to Board of Directors
23 févr. 2021 09h05 HE
|
Vallon Pharmaceuticals Inc.
- Accomplished executive leader with more than 30 years of experience in finance and operations PHILADELPHIA, PA, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ: VLON),...
Vallon Pharmaceuticals Announces Closing of Initial Public Offering
12 févr. 2021 15h30 HE
|
Vallon Pharmaceuticals Inc.
PHILADELPHIA, PA, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ: VLON) (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the...
Vallon Pharmaceuticals Announces Pricing of Initial Public Offering
09 févr. 2021 22h24 HE
|
Vallon Pharmaceuticals Inc.
PHILADELPHIA, PA, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that...